Know Cancer

or
forgot password

Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States


N/A
N/A
49 Years
Not Enrolling
Both
Leukemia, Non Hodgkin's Lymphoma, Aplastic Anemia

Thank you

Trial Information

Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States

Inclusion Criteria


- Patients with acute leukemia, lymphoma that failed to respond or relapsed after
chemotherapy or CML beyond first chronic phase.

- Patients with aplastic anemia or myelodysplasia which failed to respond to primary
therapy are eligible.

- Patients with low grade lymphoma or CLL will only be eligible if they failed two
chemotherapy regimens and have stage IV disease.

- Patients must be or three HLA A, B and DR antigen mismatched) donor.

- Patients should have adequate hepatic and renal function with a bilirubin of less
than or equal to 1.5mg%, SGPT less than or equal to 3x the upper limits of normal,
and creatine less than or equal to 1.5mg%.

- Patients with serious intercurrent medical illness are not eligible.

- Patients and their donors must provide written informed consent.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Authority:

United States: Food and Drug Administration

Study ID:

DM96-122

NCT ID:

NCT00038779

Start Date:

August 1996

Completion Date:

September 2004

Related Keywords:

  • Leukemia
  • Non Hodgkin's Lymphoma
  • Aplastic Anemia
  • Lymphoma
  • CML
  • CLL
  • AML
  • ALL
  • MDS
  • AA
  • Anemia
  • Anemia, Aplastic
  • Leukemia
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Pancytopenia
  • Hematologic Neoplasms

Name

Location

MD Anderson Cancer CenterHouston, Texas  77030-4096